{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:55:51Z","timestamp":1791471351400,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012576","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012576","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejphar.2026.179350","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:04:52Z","timestamp":1789830292000},"page":"179350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Finerenone attenuates myocardial fibrosis in myocardial infarction complicated by chronic kidney disease: an integrated study combining network pharmacology, molecular simulations, and in vivo experiments"],"prefix":"10.1016","volume":"1035","author":[{"given":"Yulong","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlin","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weipeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2224-4885","authenticated-orcid":false,"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejphar.2026.179350_bib1","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179350_bib2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179350_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24044004","article-title":"Fibrosis: types, effects, markers, mechanisms for disease progression, and its relation with oxidative stress, immunity, and inflammation","volume":"24","author":"Antar","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.ejphar.2026.179350_bib4","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ejphar.2026.179350_bib5","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/CIRCULATIONAHA.121.052792","article-title":"Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease","volume":"145","author":"Beldhuis","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179350_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057909","article-title":"Impact of chronic kidney disease on case ascertainment for hospitalised acute myocardial infarction: an English cohort study","volume":"12","author":"Bidulka","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179350_bib7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12933-021-01279-6","article-title":"The risk trajectory of different cardiovascular morbidities associated with chronic kidney disease among patients with newly diagnosed diabetes mellitus: a propensity score-matched cohort analysis","volume":"20","author":"Chao","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"10S","key":"10.1016\/j.ejphar.2026.179350_bib8","article-title":"Guideline-recommended care in patients with CKD and ischemic cardiac events vs. general population","volume":"36","author":"Cooper","year":"2025","journal-title":"A Population-Based Study: TH-PO0308"},{"issue":"8","key":"10.1016\/j.ejphar.2026.179350_bib9","first-page":"1002","article-title":"Coronary revascularization in patients with advanced chronic kidney disease","volume":"35","author":"Costanzo","year":"2019","journal-title":"Can. J. Cardiol."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179350_bib10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1159\/000518254","article-title":"Direct blood pressure-independent anti-fibrotic effects by the selective nonsteroidal mineralocorticoid receptor antagonist finerenone in progressive models of kidney fibrosis","volume":"52","author":"Droebner","year":"2021","journal-title":"Am. J. Nephrol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179350_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17020144","article-title":"Insights into protein-ligand interactions: mechanisms, models, and methods","volume":"17","author":"Du","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179350_bib12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/ndt\/gfaf009","article-title":"Tissue fibrosis in cardiorenal syndrome: crosstalk between heart and kidneys","volume":"40","author":"Dutta","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejphar.2026.179350_bib13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1146\/annurev-pharmtox-070115-095427","article-title":"Epidermal growth factor receptor transactivation: mechanisms, pathophysiology, and potential therapies in the cardiovascular system","volume":"56","author":"Forrester","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179350_bib14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.109.865352","volume":"121","author":"Fox","year":"2010","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179350_bib15","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","article-title":"Cardiac fibrosis","volume":"117","author":"Frangogiannis","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"27","key":"10.1016\/j.ejphar.2026.179350_bib16","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1093\/eurheartj\/ehac223","article-title":"Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies","volume":"43","author":"Frantz","year":"2022","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179350_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063188","article-title":"Uric acid and oxidative stress-relationship with cardiovascular, metabolic, and renal impairment","volume":"23","author":"Gherghina","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.179350_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling","volume":"168","author":"Lavall","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179350_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032971","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone improves diastolic dysfunction in preclinical nondiabetic chronic kidney disease","volume":"13","author":"Lima Posada","year":"2024","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179350_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020396","article-title":"Secreted phospholipase A(2)-IIA modulates transdifferentiation of cardiac fibroblast through EGFR transactivation: an inflammation-fibrosis link","volume":"9","author":"Martin","year":"2020","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179350_bib21","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.117.09791","article-title":"Aldosterone target NGAL (Neutrophil gelatinase-associated lipocalin) is involved in cardiac remodeling after myocardial infarction through NF\u03baB pathway","volume":"70","author":"Mart\u00ednez-Mart\u00ednez","year":"2017","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179350_bib22","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cvr\/cvz336","article-title":"Cardiac monocytes and macrophages after myocardial infarction","volume":"116","author":"Peet","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2026.179350_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000001068","article-title":"Finerenone and its cardiorenal protective effects: a meta-analysis of 21,731 patients from randomized trials","author":"Rai","year":"2025","journal-title":"Cardiol. Rev."},{"issue":"18","key":"10.1016\/j.ejphar.2026.179350_bib24","article-title":"Role of L-type Ca(2+)-channels in the vasorelaxing response to finerenone in arteries of human visceral adipose tissue","volume":"12","author":"Schinzari","year":"2024","journal-title":"Phys. Rep."},{"issue":"5\u20136","key":"10.1016\/j.ejphar.2026.179350_bib25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.lfs.2012.06.033","article-title":"Indoxyl sulfate enhances angiotensin II signaling through upregulation of epidermal growth factor receptor expression in vascular smooth muscle cells","volume":"91","author":"Shimizu","year":"2012","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179350_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2337\/dc22-1586","article-title":"Prognosis after first-ever myocardial infarction in type 1 diabetes is strongly affected by chronic kidney disease","volume":"46","author":"Smidtslund","year":"2023","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ejphar.2026.179350_bib27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11886-024-02039-0","article-title":"Management considerations for acute coronary syndromes in chronic kidney disease","volume":"26","author":"Tomey","year":"2024","journal-title":"Curr. Cardiol. Rep."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179350_bib28","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat. Med."},{"issue":"15","key":"10.1016\/j.ejphar.2026.179350_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26157440","article-title":"Cardiorenal syndrome: molecular pathways linking cardiovascular dysfunction and chronic kidney disease progression","volume":"26","author":"Vasquez","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179350_bib30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2220\/biomedres.46.83","article-title":"Finerenone alleviates the high glucose-induced fibrosis in HK-2 cells by inhibiting EMT via the TGF-\u03b21\/Smads signaling","volume":"46","author":"Wang","year":"2025","journal-title":"Biomed. Res."},{"key":"10.1016\/j.ejphar.2026.179350_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2021.10.041","article-title":"Impact of acute and chronic kidney disease on heart failure hospitalizations after acute myocardial infarction","volume":"165","author":"Yandrapalli","year":"2022","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2026.179350_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1476029","article-title":"A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist","volume":"11","author":"Zhai","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179350_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/biom15121703","article-title":"Targeting LTBP2 reveals a novel anti-cardiac remodeling mechanism of finerenone against doxorubicin-induced cardiotoxicity","volume":"15","author":"Zhang","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2026.179350_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115975","article-title":"Gene expression analysis to identify mechanisms underlying improvement of myocardial fibrosis by finerenone in SHR","volume":"220","author":"Zhou","year":"2024","journal-title":"Biochem. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926008320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926008320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:19:53Z","timestamp":1791469193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926008320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"alternative-id":["S0014299926008320"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179350","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Finerenone attenuates myocardial fibrosis in myocardial infarction complicated by chronic kidney disease: an integrated study combining network pharmacology, molecular simulations, and in vivo experiments","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179350","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179350"}}